Blackrock MuniYield Fund Inc Stock News

Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.

The stock was down by nearly one-third in premarket trading as earnings fell short of Wall Street’s expectations. CEO Mark Capone is resigning.

Myriad (MYGN) delivered earnings and revenue surprises of -25.81% and -6.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

/PRNewswire/ -- The "Molecular Diagnostics Market Share & Global Forecast, By Application, Technology, End User, Regions, Companies" report has been added to…

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of BlackRock MuniYield Fund, Inc. New York, January 29, 2020 -- Moody's Investors Service ("Moody's") has

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A leading medical society is calling on Myriad Genetics and other lab companies to share proprietary genetic testing data in a public database.

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.

NEW YORK--(BUSINESS WIRE)-- #classaction--The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN). The inv

The FDA approves BRACAnalysis CDx, Myriad Genetics' metastatic pancreatic cancer diagnostic tool for patients who are eligible for treatment with Lynparaza, a drug marketed by AstraZeneca.

Futures on the Dow Jones Industrial Average and other major U.S. stock indexes pointed to small gains.